UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) January 29, 2008

ALIGN TECHNOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

0-32259 94-3267295 (Commission File Number) (IRS Employer Identification No.)

881 Martin Avenue, Santa Clara, California95050(Address of Principal Executive Offices)(Zip Code)

(408) 470-1000

- -----

(Registrant's Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 $|_|$ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 $|_|$ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS

On January 29, 2008, Align Technology, Inc. ("Align") is issuing a press release and holding a conference call regarding its financial results for its fourth quarter and full year ended December 31, 2007. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Align is making reference to non-GAAP financial information in both the press release and the conference call. A reconciliation of non-GAAP financial measures contained in the attached press release to the comparable GAAP financial measures is contained in the attached press release and a reconciliation of these and certain other non-GAAP financial information provided on the conference call (to the extent not reconciled on such call) is contained on the Investor Relations section of our website at investor.aligntech.com.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.Description99.1Press Release of Align Technology, Inc. dated January
29, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 29, 2008

ALIGN TECHNOLOGY, INC.

By: /s/Kenneth B. Arola

Kenneth B. Arola Vice President, Finance and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.Description99.1Press Release of Align Technology, Inc. dated January
29, 2008

Align Technology Announces Fourth Quarter and Fiscal 2007 Results

Fiscal 2007 Net Revenues of \$284.3 Million Increase 38 Percent

- Q4 Net Revenue of \$72.5 Million Increase 31 Percent Year Over Year

- Q4 GAAP Net Profit of \$5.7 Million, or \$0.08 per diluted share

- Case Shipments of 50,830 Increase 30 Percent Year Over Year

SANTA CLARA, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN) today reported financial results for the fourth quarter and fiscal year 2007, ended December 31, 2007.

Total net revenues for the fourth quarter of fiscal 2007 (Q4 07) were \$72.5 million. This reflects a year-over-year increase of 31 percent compared to \$55.2 million in the fourth quarter of 2006 (Q4 06). On a sequential basis, net revenues increased slightly from \$71.5 million in the third quarter of 2007 (Q3 07). For fiscal 2007, net revenues of \$284.3 million increased 38 percent from \$206.4 million reported for fiscal 2006.

"Our fourth quarter results were a strong finish to an outstanding year in which revenue and profitability were well ahead of our original outlook," said Thomas M. Prescott, president and CEO of Align Technology. "We're entering 2008 with a robust product development pipeline, including Vivera Retainers, Invisalign Teen and Invisalign ClinAssist, which will lay the foundation for long term growth."

On a generally accepted accounting principles (GAAP) basis, net profit for Q4 07 was \$5.7 million, or \$0.08 per diluted share. This reflects a significant increase from a GAAP net loss of \$17.3 million, or \$0.27 loss per diluted share in Q4 06, and a decrease in GAAP net profit from \$9.5 million, or \$0.13 per diluted share in Q3 07. GAAP net profit for fiscal 2007 was \$35.7 million, or \$0.50 per diluted share. This compares to a net loss of \$35.0 million, or \$0.55 loss per diluted share in fiscal 2006.

Non-GAAP net profit for Q4 07 was \$9.3 million or \$0.13 per diluted share. This reflects a significant increase from a non-GAAP net loss of \$0.8 million, or \$0.01 loss per diluted share in Q4 06, and a decrease in non-GAAP net profit from \$12.6 million, or \$0.17 per diluted share in Q3 07. Non-GAAP net profit for fiscal 2007 was \$45.9 million or \$0.64 per diluted share. This compares to a non-GAAP net loss of \$11.7 million or \$0.19 loss per diluted share in fiscal 2006.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A detailed reconciliation between GAAP and non-GAAP information is contained in the tables following the financial tables of this release.

Q4 07 Operating Results

Key GAAP Operating Results	Q4 07	Q3 07	Q4 06
Gross Margin	73.6%	74.6%	68.8%
Operating Expense	\$48.4M	\$44.9M	\$56.1M
Net Profit (Loss)	\$5.7M	\$9.5M	(\$17.3M)
Earnings (Loss) Per Diluted Share (EPS)	\$0.08	\$0.13	(\$0.27)
Key Non-GAAP Operating Results	Q4 07	Q3 07	Q4 06
Non-GAAP Gross Margin	74.0%	75.0%	69.2%
Non-GAAP Operating Expense	\$45.2M	\$41.8M	\$39.7M
Non-GAAP Net Profit (Loss)	\$9.3M	\$12.6M	(\$0.8M)
Non-GAAP Earnings (Loss) Per Diluted Share	\$0.13	\$0.17	(\$0.1)

Liquidity and Capital Resources

As of December 31, 2007, Align had \$127.9 million in cash, cash equivalents, marketable securities and restricted cash, compared to \$64.1 million as of December 31, 2006.

Key Business Metrics

The following table highlights business metrics for Align's fourth quarter of 2007. Additional historical information is available on the Company's website at investor.aligntech.com.

Revenue by Channel:

Q4 07 Q4'07/Q3'07 Q4'07/Q4'06

U.S. Orthodontists U.S. GP Dentists International Training and Other Total Revenue	\$21.4M \$33.5M \$14.2M \$3.4M \$72.5M	% Change (4.9%) (3.7%) 22.4% 30.8% 1.4%	% Change 23.0% 36.7% 47.9% (8.1%) 31.3%
Average Selling Price (ASP):	Q4 07	Q4'07/Q3'07 % Change	Q4'07/Q4'06 % Change
Total Worldwide Blended ASP Total Worldwide ASP excluding	\$1,360	3.0%	3.0
Invisalign Express	\$1,470	2.8%	1.7
U.S. Orthodontists Blended ASP	\$1,240	0.8%	2.1
U.S. GP Dentists Blended ASP	\$1,320	0.8%	2.7
International	\$1,760	11.4%	2.0
Number of Cases Shipped:	Q4 07	Q4'07/Q3'07 % Change	Q4'07/Q4'06 % Change
U.S. Orthodontists - Full Invisalign	14,270	(5.8%)	22.3%
U.S. Orthodontists - Invisalign Expres	,	(2.2%)	13.3%
U.S. GP Dentists - Full Invisalign	20, 800	(4.9%)	37.3%
U.S. GP Dentists - Invisalign Express	4,630	0.7%	16.9%
International - Full Invisalign	7,950	11.0%	47.2%
International - Invisalign Express	120	(7.7%)	(14.3%)
Total Cases Shipped	50,830	(2.3%)	`30.3 %´

Number of Doctors Cases were Shipped to: U.S. Orthodontists U.S. GP Dentists International Total Doctors Cases were Shipped to Worldwide	Q4 07 3,640 10,040 2,510 16,190		
Number of Doctors Trained Worldwide: U.S. Orthodontists U.S. GP Dentists International Total Doctors Trained Worldwide	Q4 07 80 1,500 500 2,080	8,310 27,480 12,340	
Multiple Case Doctors (Cumulative as of): U.S. Orthodontists U.S. GP Dentists International	Q4 07 89.7% 87.1% 76.4%		
Doctors Starting Invisalign Treatment (Cumulative as of): U.S. Orthodontists U.S. GP Dentists International Total Doctors Starting Invisalign Treatment	Q4 07 6,710 21,600 6,610 34,920		
Doctor Utilization Rates*: U.S. Orthodontists U.S. GP Dentists International Total Utilization Rate	2.5	4.9 2.6 3.1	4.2 2.4 2.9

* Utilization = # of cases/# of doctors to whom cases were shipped

Align also recently announced that it has consolidated and re-branded the Company's extensive clinical education programs and launched a new, interactive web site to provide a suite of scalable, diverse educational resources and programs for prospective, recently certified and advanced Invisalign providers. The centerpiece of the new end-to-end approach to clinical education is http://www.AligntechInstitute.com, a dynamic, interactive web site with Invisalign product support, industry news and insights, instructor-led and web-based CE events and more.

Business Outlook

As announced on January 9, 2008, Align Technology is expected to deliver new products in 2008 with features such as staged delivery with Invisalign ClinAssist and replacement aligners included with Invisalign Teen. These new products will have a significantly higher amount of deferred revenue as a percentage of their average selling price. Therefore, as new products increase as a percentage of total net revenues in the latter part of 2008, deferred revenue on the balance sheet will increase substantially and will be recognized as revenue in future periods.

For the first quarter 2008 (Q1 08), Align Technology expects net revenues to be in a range of \$70.4 million to \$73.0 million. Earnings per diluted share for Q1 08 is expected to be in a range of \$0.01 to \$0.03. Stock-based stock compensation expense for Q1 08 is expected to be approximately \$3.7 million.

For fiscal 2008, Align Technology expects net revenues to be in a range of \$320.0 million to \$330.0 million. This reflects an increase in deferred revenue of \$9 million to \$18 million primarily associated with new products, which will be recognized in future periods, bringing the Company's total deferred revenue balance at the end of 2008 to a range of \$20 million to \$30 million. Earnings per diluted share for fiscal 2008 is expected to be in a range of \$0.40 to \$0.45. Stock-based compensation expense for fiscal 2008 is expected to be approximately \$18.0 million. A more comprehensive business outlook is available following the financial tables of this release.

Align Web cast and Conference Call

Align Technology will host a conference call today, January 29, 2008 at 4:30 p.m. ET, 1:30 p.m. PT, to review its fourth quarter and fiscal 2007 results, discuss future operating trends and business outlook. The conference call will also be webcast live via the Internet. To access the webcast, go to the "Events & Presentations" section under Company Information on Align Technology's Investor Relations web site at http://investor.aligntech.com. To access the conference call, please dial 201-689-8341 approximately fifteen minutes prior to the start of the call. If you are unable to listen to the call, an archived web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with account number 292 followed by # and conference number 268148 followed by #. The replay must be accessed from international locations by dialing 201-612-7415 and using the same account and conference numbers referenced above. The telephonic replay will be available through 4:30 p.m. ET on February 12, 2008.

About Align Technology, Inc.

Align Technology designs, manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal or ceramic brackets and wires, Invisalign significantly reduces the aesthetic and other limitations associated with braces. Invisalign is appropriate for treating adults and older teens. Align Technology was founded in March 1997 and received FDA clearance to market Invisalign in 1998. To learn more about Invisalign or to find a certified Invisalign doctor in your area, please visit http://www.invisalign.com or call 1-800-INVISIBLE.

About Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principals (GAAP), we use the following non-GAAP financial measures: non-GAAP gross profit, gross margin, profit (loss) from operations, net profit (loss), earnings (loss) per share, and operating expenses, which exclude stock-based compensation and the Patients First Program. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the tables captioned "Reconciliation of GAAP to Non-GAAP Key Financial Metrics" and "Business Outlook Summary" included at the end of this release.

We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our "core operating performance." Management believes that "core operating performance" represents Align's performance in the ordinary, ongoing and customary course of its operations. Accordingly, management excludes from "core operating performance" certain expenses and expenditures that may not be indicative of our operating performance including not only non-cash charges, such as stock-based compensation, but also discrete cash charges that are infrequent or one-time in nature. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal evaluation of period-to-period comparisons. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are provided to and used by our institutional investors and the analyst community to help them analyze the health of our business.

In addition to the reasons stated above, which are generally applicable to each of the items we exclude from our non-GAAP financial measures, we believe it is appropriate to exclude Stock-Based Compensation for the following reasons. Align adopted SFAS 123(R), beginning in its fiscal year 2006. When evaluating the performance of our business, we do not consider stock-based compensation charges. In contrast, we do consider and managers are held accountable for cash-based compensation and such amounts are included in our operating plan. Further, when considering the impact of equity award grants, Align places a greater emphasis on overall shareholder dilution rather than the accounting charges associated with such grants.

Forward-Looking Statement

This news release, including the tables below, contains forward-looking statements, including statements regarding Align's anticipated financial results and certain business metrics for the first quarter and full year of 2008, including anticipated revenue and deferred revenue, gross profit, gross margin, operating expense, net profit, earnings per share, percentage of revenue by channel, case shipments and average selling prices and statements regarding the anticipated introduction of Invisalign ClinAssist and Invisalign Teen and the expectation that these new products will increase as a percentage of sales in the later part of 2008. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, continued customer demand for Invisalign and new products, the timing of case submissions from our doctors within a quarter, acceptance of Invisalign by consumers and dental professionals, Align's third party manufacturing processes and personnel, foreign operational, political and other risks relating to Align's international manufacturing operations, Align's ability to protect its intellectual property rights, competition from manufacturers of traditional braces and new competitors, Align's ability to develop and successfully introduce new products and product enhancements, and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the fiscal year ended December 31, 2006, which was filed with the Securities and Exchange Commission on March 12, 2007, and its Quarterly Reports on Form 10-Q. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Investor Relations Contact Shirley Stacy Align Technology, Inc. (408) 470-1150 sstacy@aligntech.com Press Contact Shannon Mangum Henderson Ethos Communication, Inc. (678) 540-9222 align@ethoscommunication.com

ALIGN TECHNOLOGY, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data)

		hs Ended December 31, 2006	December	Ended December 31, 2006
Net revenues	\$72,517	\$55,191	\$284,332	\$206,354
Cost of revenues	19,127	17,197	75,035	64,775
Gross profit	53,390	37,994	209,297	141,579
Operating expenses: Sales and marketing General and administrative Research and development Patients First Program	26,502 15,266 6,610	14,649	98,231 53,280 25,727 (1,796)	64,305
Total operating expenses	48,378	56,061	175,442	179,115
Profit (loss) from operations	5,012	(18,067)	33,855	(37,536)
Interest and other income, net	852	1,008	3,095	3,401
Profit (loss) before income taxes	5,864	(17,059)	36,950	(34,135)
Provision for income taxes	(196)	(210)	(1,226)	(828)
Net profit (loss)	\$5,668	\$(17,269)	\$35,724	\$(34,963)
Net profit (loss) per share - basic - diluted	\$0.08 \$0.08	• • • • •		
Shares used in computing net prof (loss) per share - basic - diluted	it 68,562 71,864	•	,	

ALIGN TECHNOLOGY, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)

ASSETS	December 31, 2007	December 31, 2006
Current assets: Cash and cash equivalents Restricted cash Marketable securities, short-term Accounts receivable, net Inventories, net Other current assets Total current assets	\$89,119 21 38,771 44,850 2,910 8,846 184,517	\$55,113 93 8,931 33,635 3,090 7,227 108,089
Property and equipment, net Goodwill and intangible assets, net Other long-term assets	25,320 11,093 1,831	26,904 14,302 2,263
Total assets	\$222,761	\$151,558
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities: Line of credit Accounts payable Accrued liabilities Deferred revenue Total current liabilities	\$- 9,222 39,875 12,362 61,459	\$11,500 5,034 40,307 10,942 67,783
Other long term liabilities	148	219
Total liabilities	61,607	68,002
Total stockholders' equity	161,154	83,556
Total liabilities and stockholders' equity	\$222,761	\$151,558

ALIGN TECHNOLOGY, INC. RECONCILIATION OF GAAP TO NON-GAAP KEY FINANCIAL METRICS

Reconciliation of GAAP to Non-GAAP Gross Profit (in thousands, except percentages)

	Three Months Ended		
	December 31,	September 30,	December 31,
	2007	2007	2006
GAAP Gross profit Stock based compensation expense	\$53,390 291	\$53,319 259	\$37,994 185
Non-GAAP Gross profit	\$53,681	\$53,578	\$38,179
Non-GAAP Gross margin	74.0%	75.0%	69.2%

Reconciliation of GAAP to Non-GAAP Operating Expenses (in thousands)

	Three Months Ended		
	December 31,	September 30,	December 31,
	2007	2007	2006
GAAP Operating expenses Stock based compensation expense	\$48,378 3,145	. ,	\$56,061 1,977
Patients First Program			14,343
Non-GAAP Operating expenses	\$45,233	\$41,795	\$39,741

Reconciliation of GAAP to Non-GAAP Net Profit (Loss) (in thousands, except per share amounts)

	-	hree Months En September 30, 2007	
GAAP Net profit (loss) Stock based compensation expense Patients First Program Tax effect of stock based compensation expense	\$5,668 3,436 - 160	3,388 -	\$(17,269) 2,162 14,343
Non-GAAP Net profit (loss)	\$9,264	\$12,587	\$(764)
Diluted Net profit (loss) per shar GAAP Non-GAAP	e: \$0.08 \$0.13		\$(0.27) \$(0.01)
Shares used in computing diluted n profit (loss) per share	et 71,864	72,230	64,252

Summary of Stock Based Compensation Expense (in thousands)

	Three Months Ended		
	December	31, September	30, December 31,
	2007	2007	2006
Cost of revenues	\$291	\$259	\$185
Sales and marketing	1,169	1,301	737
General and administrative	1,508	1,403	922
Research and development	468	425	318
Total stock based compensation			
expense	\$3,436	\$3,388	\$2,162

ALIGN TECHNOLOGY, INC. RECONCILIATION OF GAAP TO NON-GAAP KEY FINANCIAL METRICS

Reconciliation of GAAP to Non-GAAP Gross Profit (in thousands, except percentages)

	Years Ended		
	December 31,	December 31,	
	2007	2006	
GAAP Gross profit	\$209,297	\$141,579	
Stock based compensation expense	994	700	
Non-GAAP Gross profit	\$210,291	\$142,279	
Non-GAAP Gross margin	74.0%	68.9%	

Reconciliation of GAAP to Non-GAAP Operating Expenses (in thousands)

	Years Ended		
	December 31,	December 31,	
	2007	2006	
GAAP Operating expenses	\$175,442	\$179,115	
Stock based compensation expense	11,217	8,210	
Patients First Program	(1,796)	14,343	
Non-GAAP Operating expenses	\$166,021	\$156,562	

Reconciliation of GAAP to Non-GAAP Net Profit (Loss) (in thousands, except per share amounts)

	Years Ended		
	December 31,	December 31,	
	2007	2006	
GAAP Net profit (loss)	\$35,724	\$(34,963)	
Stock based compensation expense	12,211	8,910	
Patients First Program	(1,796)	14,343	
Tax effect of stock based			
compensation expense	(214)	-	
Non-GAAP Net profit (loss)	\$45,925	\$(11,710)	
Diluted Net profit (loss) per share:			
GAAP	\$0.50	\$(0.55)	
Non-GAAP	\$0.64	\$(0.19)	
Shares used in computing diluted net			
profit (loss) per share	71,444	63,246	

Summary of Stock Based Compensation Expense (in thousands)

	Years Ended	
	December 31,	December 31,
	2007	2006
Cost of revenues	\$994	\$700
Sales and marketing	4,225	2,862
General and administrative	5,443	4,054
Research and development	1,549	1,294
Total stock based compensation		* 2 242
expense	\$12,211	\$8,910

ALIGN TECHNOLOGY, INC. BUSINESS OUTLOOK SUMMARY (unaudited)

The outlook figures provided below and elsewhere in this press release are approximate in nature since Align's business outlook is difficult to predict. Align's future performance involves numerous risks and uncertainties and the company's results could differ materially from the outlook provided. Some of the factors that could affect Align's future financial performance and business outlook are set forth under "Forward Looking Information" above in this press release.

Financials:

(in millions, except per share amounts and pe

	Q1 2008	FY 2008
Net Revenue	\$70.4 - \$73.0	\$320.0 - \$330.0
Gross Profit	\$50.8 - \$53.5	\$237.6 - \$248.0
Gross Margin	72.2% - 73.2%	74.2% - 75.1%
Operating Expenses	\$50.4 - \$51.9	\$210.8 - \$218.8
Net Profit	\$0.7 - \$2.2	\$29.3 - \$32.7
Net Profit %	1% - 3%	9% - 10%
Net Profit per Diluted Share	\$0.01 - \$0.03	\$0.40 - \$0.45
Increase in Deferred Revenue		\$9.0 - \$18.0
Total Deferred Revenue Balance		\$20.0 - \$30.0
Stock Based Compensation Expense: Cost of Revenues Operating Expenses Total Stock Based Compensation Expense	\$0.3 \$3.4 \$3.7	\$1.2 \$16.8 \$18.0
Business Metrics: Case Shipments Cash DSO Capex Depreciation & Amortization Diluted Shares Outstanding	Q1 2008 50.0K - 51.5K \$117M - \$122M ~56 days \$4.0M - \$6.0M \$2.0M - \$3.0M 71.2M	FY 2008 226.7K - 237.2K \$160M - \$170M ~56 days \$10.0M - \$14.0M \$13.0M - \$14.0M 73.2M